1. Home
  2. LILAK vs HROW Comparison

LILAK vs HROW Comparison

Compare LILAK & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Latin America Ltd. Class C

LILAK

Liberty Latin America Ltd. Class C

HOLD

Current Price

$7.71

Market Cap

1.7B

ML Signal

HOLD

Logo Harrow Inc.

HROW

Harrow Inc.

HOLD

Current Price

$44.47

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LILAK
HROW
Founded
2017
1998
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LILAK
HROW
Price
$7.71
$44.47
Analyst Decision
Hold
Strong Buy
Analyst Count
1
8
Target Price
$8.20
$68.86
AVG Volume (30 Days)
944.0K
581.9K
Earning Date
02-18-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,433,000,000.00
$250,042,000.00
Revenue This Year
$1.37
$38.96
Revenue Next Year
N/A
$43.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
47.83
52 Week Low
$4.23
$20.85
52 Week High
$9.13
$54.85

Technical Indicators

Market Signals
Indicator
LILAK
HROW
Relative Strength Index (RSI) 51.50 40.33
Support Level $7.34 $44.55
Resistance Level $8.11 $47.86
Average True Range (ATR) 0.28 2.84
MACD 0.10 -0.80
Stochastic Oscillator 69.81 5.95

Price Performance

Historical Comparison
LILAK
HROW

About LILAK Liberty Latin America Ltd. Class C

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Share on Social Networks: